Antimelanoma differentiation antigen 5-positive dermatomyositis: an update.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
pubmed:
15
7
2024
medline:
15
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
Antimelanoma differentiation antigen 5-dermatomyositis (MDA5-DM) is a complex and serious systemic autoimmune disease that primarily affects the skin and lungs. In this review, we aimed to provide new insights into the clinical features, pathogenesis, and practical management approach for this disease. Although lung lesions are prominent in most patients with MDA5-DM, they are now recognized as heterogeneous diseases. Peripheral blood lymphocyte count can serve as a simple and reliable laboratory parameter for categorizing MDA5-DM into three subgroups: mild, medium, and severe. Recent studies have implicated viral infection, genetic factors, autoimmunity against MDA5, multiple immune cells, and interferons as significant contributors to MDA5-DM pathogenesis. In addition to traditional treatments with glucocorticoids and immunosuppressants, many new approaches, including new biologics and targeted agents, have been explored. Additionally, infection is a common complication of MDA5-DM, and prophylaxis or treatment of the infection is as important as treating the primary disease. Knowledge of clinical characteristics and pathogenesis of MDA5-DM has grown in recent years. Although many new therapeutic approaches have been explored, further studies are required to confirm their efficacy.
Identifiants
pubmed: 39007238
doi: 10.1097/BOR.0000000000001034
pii: 00002281-990000000-00126
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol 2024; 20:48–62.
McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14:290–302.
David P, Sinha S, Iqbal K, et al. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine 2024; 104:105136.
Tonutti A, Motta F, Ceribelli A, et al. Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: a case report and systematic literature review. Front Immunol 2022; 13:937667.
Jin Q, Fu L, Yang H, et al. Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med 2023; 293:494–507.
Mammen AL, Allenbach Y, Stenzel W, Benveniste O. 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December. Neuromuscul Disord 2020; 30:70–92.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76:1955–1964.
Damoiseaux J, Mammen AL, Piette Y, et al. 256(th) ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8–10 October. Neuromuscul Disord 2022; 32:594–608.
Chen X, Jiang W, Jin Q, et al. Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease. RMD Open 2023; 9:e003150.
Fuzzi E, Gatto M, Zen M, et al. Anti-MDA5 dermatomyositis: an update from bench to bedside. Curr Opin Rheumatol 2022; 34:365–373.
Jin Q, Lin S, Chen X, et al. Spontaneous pneumomediastinum in anti-MDA5-positive dermatomyositis: prevalence, risk factors, and prognosis. Semin Arthritis Rheum 2024; 65:152352.
Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 2020; 95:e70–e78.
Yang Q, Lyu K, Li J, et al. Antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses. Clin Exp Rheumatol 2022; 40:304–308.
Xu L, You H, Wang L, et al. Identification of three different phenotypes in anti–melanoma differentiation–associated gene 5 antibody–positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol 2023; 75:609–619.
Nishina N, Sato S, Masui K, et al. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open 2020; 6:e001202.
Toquet S, Granger B, Uzunhan Y, et al. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev 2021; 20:102788.
Kitajima T, Funauchi A, Nakajima T, et al. Antimelanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines. J Rheumatol 2022; 49:1158–1162.
Mecoli CA, Yoshida A, Paik JJ, et al. Presence and implications of anti-angiotensin converting enzyme-2 immunoglobulin m antibodies in anti-melanoma-differentiation-associated 5 dermatomyositis. ACR Open Rheumatol 2022; 4:457–463.
Rothwell S, Chinoy H, Lamb JA, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 2019; 78:996–1002.
Gono T, Kawaguchi Y, Kuwana M, et al. Brief report: Association of HLA-DRB1∗0101/∗0405 with susceptibility to antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 2012; 64:3736–3740.
Chen Z, Wang Y, Kuwana M, et al. HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis. J Rheumatol 2017; 44:1389–1393.
Lin JM, Zhang YB, Peng QL, et al. Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population. HLA 2017; 90:354–359.
Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 2018; 77:602–611.
Guo L, Zhang X, Pu W, et al. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology 2023; 62:2320–2324.
Xiao Y, Xie S, Li H-D, et al. Characterised intron retention profiles in muscle tissue of idiopathic inflammatory myopathy subtypes. Ann Rheum Dis 2024; 83:901–914.
Seto N, Torres-Ruiz JJ, Carmona-Rivera C, et al. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight 2020; 5:e134189.
Ma W, Zhu J, Bai L, et al. The role of neutrophil extracellular traps and proinflammatory damage-associated molecular patterns in idiopathic inflammatory myopathies. Clin Exp Immunol 2023; 213:202–208.
Bai L, Zhu J, Ma W, et al. Neutrophil extracellular traps are involved in the occurrence of interstitial lung disease in a murine experimental autoimmune myositis model. Clin Exp Immunol 2024; 215:126–136.
Wang K, Zhao J, Wu W, et al. RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-α. Front Immunol 2021; 12:743704.
Van Gompel E, Demirdal D, Fernandes-Cerqueira C, et al. Autoantibodies against the melanoma differentiation–associated protein 5 in patients with dermatomyositis target the helicase domains. Rheumatology 2024; 63:1466–1473.
Zaizen Y, Okamoto M, Azuma K, et al. Enhanced immune complex formation in the lungs of patients with dermatomyositis. Respir Res 2023; 24:86.
Ichimura Y, Konishi R, Shobo M, et al. Autoimmunity against melanoma differentiation–associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice. Proc Natl Acad Sci USA 2024; 121:e2313070121.
Okiyama N, Ichimura Y, Shobo M, et al. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis. Ann Rheum Dis 2021; 80:1201–1208.
Chen F, Wang D, Shu X, et al. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int 2012; 32:3909–3915.
Lin S, Zhang Y, Cao Z, et al. Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis. Clin Chim Acta 2023; 543:117321.
Jiang L, Wang Y, Peng Q, et al. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol 2019; 38:1655–1663.
Wang K, Zhao J, Chen Z, et al. CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology 2019; 58:511–521.
Ye Y, Chen Z, Jiang S, et al. Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun 2022; 13:6458.
Xu YT, Cao ZY, Lin S, et al. Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal infection risk in antimelanoma differentiation associated gene 5 dermatomyositis. Clin Exp Rheumatol 2024; 42:237–245.
Thuner J, Coutant F. IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies. Autoimmun Rev 2023; 22:103420.
Fukada A, Fujisawa T, Hozumi H, et al. Prognostic role of interferon-λ3 in anti–melanoma differentiation–associated gene 5–positive dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol 2024; 76:796–805.
Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti–melanoma differentiation–associated gene 5–positive dermatomyositis. Arthritis Rheumatol 2020; 72:488–498.
Sasai T, Nakashima R, Tsuji H, et al. Long-term prognosis of antimelanoma differentiation–associated gene 5–positive dermatomyositis with interstitial lung disease. J Rheumatol 2023; 50:1454–1461.
Gono T, Masui K, Sato S, Kuwana M. Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy. Front Med (Lausanne) 2022; 9:883699.
Hata K, Kotani T, Matsuda S, et al. Aggressive multicombination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease. Int J Rheum Dis 2023; 27:e14999.
Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 2019; 381:291–293.
Harada H, Shoda H, Tsuchiya H, et al. Baricitinib for antimelanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease. Rheumatol Int 2024; 44:961–971.
Oba Y, Yamanouchi M, Ikuma D, et al. Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction. SAGE Open Med Case Rep 2022; 10: 2050313x221141277.
Yamazaki S, Shimizu M, Yakabe A, et al. Successful treatment with tofacitinib for antimelanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature. Immunol Med 2024; 47:110–117.
Xue Y, Zhang J, Deng J, et al. Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients. Ann Rheum Dis 2023; 82:1499–1501.
So H, Wong VTL, Lao VWN, et al. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 2018; 37:1983–1989.
Ge Y, Li S, Tian X, et al. Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol 2021; 40:2311–2317.
Peskin M, Mostowy M, Velez J, et al. Clinical improvement in early onset interstitial lung disease using rituximab in children with antimelanoma differentiation-associated gene 5-positive juvenile dermatomyositis. J Rheumatol 2024; 51:69–74.
Bay P, de Chambrun MP, Rothstein V, et al. Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease. J Autoimmun 2022; 133:102941.
Watanabe T, Taniguchi M, Ogura S, et al. Effectiveness and safety of plasma exchange for anti-MDA5 antibody–positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: a case series. Ther Apher Dial 2024; 28:432–441.
Sasaki N, Nakagome Y, Kojima A, et al. Early initiation of plasma exchange therapy for anti-MDA5(+)dermatomyositis with refractory rapidly progressive interstitial lung disease. Intern Med 2024; 63:213–219.
Shirai T, Machiyama T, Sato H, et al. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe antimelanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. Clin Exp Rheumatol 2023; 41:291–300.
Holzer MT, Nies JF, Oqueka T, et al. Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis. Chest 2023; 163:e1–e5.
Ostendorf L, Muench F, Thormählen L, et al. Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab. RMD Open 2023; 9:e003238.
Chua CG, Chai GT, Lim XR, et al. Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab. Clin Exp Rheumatol 2024; 42:460–461.
Huang K, Vinik O, Shojania K, et al. Clinical spectrum and therapeutics in Canadian patients with antimelanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int 2019; 39:1971–1981.
Lian QY, Chen A, Zhang JH, et al. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature. Clin Rheumatol 2023; 42:941–947.
Müller F, Boeltz S, Knitza J, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 2023; 401:815–818.
Pecher AC, Hensen L, Klein R, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 2023; 329:2154–2162.
Taubmann J, Knitza J, Müller F, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology 2024; 63:e12–e14.
Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N Engl J Med 2024; 390:687–700.
Sabbagh S, Almeida de Jesus A, Hwang S, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain 2019; 142:e59.
Le Voyer T, Gitiaux C, Authier F-J, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology 2021; 60:5801–5808.
Ishikawa Y, Kasuya T, Fujiwara M, Kita Y. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine (Baltimore) 2020; 99:e21943.
Stager K, Wise L. MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin. BMJ Case Rep 2020; 13:e236431.
Peringeth G, Abbi B, Mahmood S. Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy. BMJ Case Rep 2024; 17:e253960.
Quintero-González DC, Navarro-Beleño K, López-Gutiérrez LV, et al. Cardiac involvement in anti-MDA5 dermatomyositis: a case-based review. Clin Rheumatol 2022; 42:949–958.
Roeser A, Hadjadj J, Prat L, et al. Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease. Rheumatology 2023; 62:e246–e248.
Matsuda KM, Yoshizaki A, Kuzumi A, et al. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol 2020; 47:483–489.
Huang L, Fu Q, Ye Y, et al. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther 2021; 23:232.
Chen X, Shu X, He L, et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis. Rheumatology 2023; 62:3302–3309.
Liu L, Zhang Y, Liu S, et al. Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with antimelanoma differentiation-associated gene 5. Rheumatology 2023; 62:3095–3100.
Chen X, Lin S, Jin Q, et al. Prevalence, risk factors, and mortality of invasive pulmonary Aspergillosis in patients with Anti-MDA5+ dermatomyositis: a retrospective study in China. J Inflamm Res 2024; 17:3247–3257.